7705 related articles for article (PubMed ID: 2654298)
1. Beta 2 microglobulin expression in normal melanocytes, nevocellular nevi, and malignant melanomas.
Takata M; Hirone T; Matsumura H
J Invest Dermatol; 1989 May; 92(5 Suppl):243S-247S. PubMed ID: 2654298
[TBL] [Abstract][Full Text] [Related]
2. Major histocompatibility antigens and mononuclear inflammatory infiltrate in benign nevomelanocytic proliferations and malignant melanoma.
Ruiter DJ; Bhan AK; Harrist TJ; Sober AJ; Mihm MC
J Immunol; 1982 Dec; 129(6):2808-15. PubMed ID: 6183345
[TBL] [Abstract][Full Text] [Related]
3. PRAME Expression in Melanocytic Tumors.
Lezcano C; Jungbluth AA; Nehal KS; Hollmann TJ; Busam KJ
Am J Surg Pathol; 2018 Nov; 42(11):1456-1465. PubMed ID: 30045064
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical analysis of malignant melanomas and nevocellular nevi with monoclonal antibodies to distinct monomorphic determinants of HLA antigens.
Ruiter DJ; Bergman W; Welvaart K; Scheffer E; van Vloten WA; Russo C; Ferrone S
Cancer Res; 1984 Sep; 44(9):3930-5. PubMed ID: 6204749
[TBL] [Abstract][Full Text] [Related]
5. The differential reactivity of benign and malignant nevomelanocytic lesions with mouse monoclonal antibody TNKH1.
Nakanishi T; Hashimoto K
Cancer; 1987 Apr; 59(7):1340-4. PubMed ID: 3545436
[TBL] [Abstract][Full Text] [Related]
6. Analysis of major histocompatibility antigens and the mononuclear cell infiltrate in halo nevi.
Bergman W; Willemze R; de Graaff-Reitsma C; Ruiter DJ
J Invest Dermatol; 1985 Jul; 85(1):25-9. PubMed ID: 3159801
[TBL] [Abstract][Full Text] [Related]
7. Fibrosis in regressing melanoma versus nonfibrosis in halo nevus upon melanocyte disappearance: could it be related to a different cytokine microenvironment?
Moretti S; Spallanzani A; Pinzi C; Prignano F; Fabbri P
J Cutan Pathol; 2007 Apr; 34(4):301-8. PubMed ID: 17381800
[TBL] [Abstract][Full Text] [Related]
8. Expression of ligands to NKp46 in benign and malignant melanocytes.
Cagnano E; Hershkovitz O; Zilka A; Bar-Ilan A; Golder A; Sion-Vardy N; Bogdanov-Berezovsky A; Mandelboim O; Benharroch D; Porgador A
J Invest Dermatol; 2008 Apr; 128(4):972-9. PubMed ID: 17972960
[TBL] [Abstract][Full Text] [Related]
9. Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas.
Elder DE; Rodeck U; Thurin J; Cardillo F; Clark WH; Stewart R; Herlyn M
Cancer Res; 1989 Sep; 49(18):5091-6. PubMed ID: 2548711
[TBL] [Abstract][Full Text] [Related]
10. The initial steps of tumor progression in melanocytic lineage: a histochemical approach.
Wollina U; Kilian U; Henkel U; Schaarschmidt H; Knopf B
Anticancer Res; 1991; 11(4):1405-14. PubMed ID: 1746897
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibody (AFH1) immunoreactive on morphologically abnormal basal melanocytes within dysplastic nevi, nevocellular nevus nests, and melanoma.
Aronson PJ; Ito K; Fukaya T; Hashimoto K; Mehregan AH
J Invest Dermatol; 1988 Apr; 90(4):452-8. PubMed ID: 3280697
[TBL] [Abstract][Full Text] [Related]
12. Phenotyping of lesions of melanocyte origin with monoclonal antibodies to melanoma-associated antigens and to HLA antigens.
Natali PG; Bigotti A; Cavaliere R; Nicotra MR; Ferrone S
J Natl Cancer Inst; 1984 Jul; 73(1):13-24. PubMed ID: 6376904
[TBL] [Abstract][Full Text] [Related]
13. Melanocyte-specific immune response in a patient with multiple regressing nevi and a history of melanoma.
Speeckaert R; van Geel N; Luiten RM; van Gele M; Speeckaert M; Lambert J; Vermaelen K; Tjin EP; Brochez L
Anticancer Res; 2011 Nov; 31(11):3697-703. PubMed ID: 22110189
[TBL] [Abstract][Full Text] [Related]
14. Melanocyte mutation in halo naevus and malignant melanoma?
Bennett C; Copeman PW
Br J Dermatol; 1979 Apr; 100(4):423-6. PubMed ID: 378250
[TBL] [Abstract][Full Text] [Related]
15. Increased intraepidermal melanocyte frequency and size in dysplastic melanocytic nevi and cutaneous melanoma. A comparative quantitative study of dysplastic melanocytic nevi, superficial spreading melanoma, nevocellular nevi, and solar lentigines.
Rhodes AR; Melski JW; Sober AJ; Harrist TJ; Mihm MC; Fitzpatrick TB
J Invest Dermatol; 1983 May; 80(5):452-9. PubMed ID: 6341476
[TBL] [Abstract][Full Text] [Related]
16. Recombinant gamma-interferon induces changes in expression and shedding of antigens associated with normal human melanocytes, nevus cells, and primary and metastatic melanoma cells.
Herlyn M; Guerry D; Koprowski H
J Immunol; 1985 Jun; 134(6):4226-30. PubMed ID: 2985706
[TBL] [Abstract][Full Text] [Related]
17. The immune response in halo nevi.
Zeff RA; Freitag A; Grin CM; Grant-Kels JM
J Am Acad Dermatol; 1997 Oct; 37(4):620-4. PubMed ID: 9344203
[TBL] [Abstract][Full Text] [Related]
18. [Dysplastic melanocytic nevi: quantitative ultrastructural investigation comparing intraepidermal melanocytes of dysplastic melanocytic nevi, superficial spreading melanoma, nevocellular nevi, and normal skin].
Seki Y; Fitzpatrick TB; Rhodes AR
Nihon Hifuka Gakkai Zasshi; 1988 Oct; 98(11):1093-103. PubMed ID: 3225938
[No Abstract] [Full Text] [Related]
19. Analysis of HLA antigen expression in benign and malignant melanocytic lesions reveals that upregulation of HLA-G expression correlates with malignant transformation, high inflammatory infiltration and HLA-A1 genotype.
Ibrahim EC; Aractingi S; Allory Y; Borrini F; Dupuy A; Duvillard P; Carosella ED; Avril MF; Paul P
Int J Cancer; 2004 Jan; 108(2):243-50. PubMed ID: 14639610
[TBL] [Abstract][Full Text] [Related]
20. Malignant melanoma and nevocellular nevi. Histogenesis and relationships. Fluorescence-microscopic and catamnestic photographic studies.
Paul E
Norm Pathol Anat (Stuttg); 1984; 48():1-112. PubMed ID: 6701085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
